Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in pediatric NTRK fusion-positive tumors
NL-OMON59704Phase 2Completed
- Sponsor
- Bayer Consumer Health
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of larotrectinib in Nonhematologic neoplasms, Central nervous system tumor harboring NTRK gene fusion, congenital fibrosarcoma (CFS) and 3 more, sponsored by Bayer Consumer Health. Primary endpoints: Dose-limiting toxicity, Treatment-emergent adverse events and 2 more. Started Dec 2018; status: completed.
02
Drugs
larotrectinib
03
Conditions
Nonhematologic neoplasmsCentral nervous system tumor harboring NTRK gene fusioncongenital fibrosarcoma (CFS)mesoblastic nephroma (CMN)secretory breast carcinoma (SBC)
Beyond the preview
Go deeper on NL-OMON59704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59704.